Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. Participants will be randomized to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent. Belantamab mafodotin is a targeted cancer treatment that works against multiple myeloma cells. It combines a homing device (an antibody) with a powerful cell-killing drug (a toxin), delivering the toxin directly to

Trial Details

NCT ID
NCT07285239
Phase
PHASE3
Sponsor
PrECOG, LLC.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Arm A: Belantamab Mafodotin
  • Arm B: Daratumumab Hyaluronidase
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
Locations (sample)
  • La Crosse, Wisconsin, United States|43.80136,-91.23958

Key Eligibility Criteria

  • Eligibility Criteria:
  • Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not …
  • Patient must be considered ineligible for autologous stem cell transplantation by the treating physician because of their age (≥ 70 years) or aged …
  • Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →